BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Core Insights - BriaCell Therapeutics Corp. announced updated results from its ongoing Phase 2 study of Bria-IMT™ in combination with checkpoint inhibitors for patients with advanced metastatic breast cancer [1] Group 1: Study Results - The Phase 2 study reported sustained complete resolution of temporal lobe brain metastasis and continued reduction of an orbital tumor after more than 18 months of treatment [2][5] - A heavily pre-treated patient, who had failed eight prior treatment regimens, demonstrated no detectable disease in the right temporal lobe and ongoing tumor shrinkage in the orbital lesion after 20 months [5][6] - Serial imaging confirmed the right temporal lobe lesion was no longer detectable at 8, 11, and 20 months [3][5] Group 2: Patient Profile - The patient had previously undergone eight treatment regimens, including an antibody-drug conjugate (ADC), before starting therapy with Bria-IMT plus checkpoint inhibition [5][7] - The patient has completed 29 treatment cycles and has been part of BriaCell's Phase 2 study for over 21 months [5][7] Group 3: Company Perspective - Dr. William V. Williams, BriaCell's President & CEO, stated that the results suggest Bria-IMT may provide durable immunotherapeutic benefits for late-stage breast cancer patients with brain metastases who have exhausted other options [6]